Advertisement

Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial

Published:February 10, 2012DOI:https://doi.org/10.1053/j.gastro.2012.01.035

      Background & Aims

      We investigated the efficacy of adalimumab for inducing and maintaining mucosal healing in patients with Crohn's disease (CD).

      Methods

      A randomized, double-blind, placebo-controlled trial (extend the safety and efficacy of adalimumab through endoscopic healing [EXTEND]) evaluated adalimumab for induction and maintenance of mucosal healing in 135 adults with moderate to severe ileocolonic CD. The baseline degree of mucosal ulceration was documented by ileocolonoscopy. All patients received induction therapy (subcutaneous adalimumab 160/80 mg at weeks 0/2). At week 4, patients were randomly assigned to groups given 40 mg adalimumab or placebo every other week through week 52. Open-label adalimumab was given to patients with flares or no response, starting at week 8. Mucosal healing was reassessed by ileocolonoscopy at weeks 12 and 52.

      Results

      Twenty-seven percent of patients receiving adalimumab had mucosal healing at week 12 (the primary end point) versus 13% given placebo (P = .056). At week 52, rates of mucosal healing were 24% and 0, respectively (P < .001). Remission rates, based on the Crohn's Disease Endoscopic Index of Severity, were 52% for adalimumab and 28% for placebo at week 12 (P = .006) and 28% and 3%, respectively, at week 52 (P < .001). Rates of clinical remission based on the Crohn's Disease Activity Index were greater among patients given continuous adalimumab therapy versus placebo at weeks 12 (47% vs 28%; P = .021) and 52 (33% vs 9%; P = .001). Five serious (1 during induction and 4 during open-label therapy) and 3 opportunistic infections (1 in each group during double-blind therapy and 1 during open-label therapy) were reported (n = 135).

      Conclusions

      Following induction therapy with adalimumab, patients with moderately to severely active CD who continue to receive adalimumab are more likely to achieve mucosal healing than those given placebo.

      Keywords

      Abbreviations used in this paper:

      CDAI (Crohn's Disease Activity Index), CDEIS (Crohn's Disease Endoscopic Index of Severity), CR-70 (Decrease in CDAI of at least 70 points from baseline), CR-100 (Decrease in CDAI of at least 100 points from baseline), CRP (C-reactive protein), SES-CD (Simple Endoscopic Score for Crohn's Disease), TNF (tumor necrosis factor)
      To read this article in full you will need to make a payment
      AGA Member Login
      Login with your AGA username and password.
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Rutgeerts P.
        • Diamond R.H.
        • Bala M.
        • et al.
        Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.
        Gastrointest Endosc. 2006; 63: 433-442
        • Cellier C.
        • Sahmoud T.
        • Froguel E.
        • et al.
        Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease: a prospective multicentre study of 121 cases.
        Gut. 1994; 35: 231-235
        • Jones J.
        • Loftus Jr, E.V.
        • Panaccione R.
        • et al.
        Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.
        Clin Gastroenterol Hepatol. 2008; 6: 1218-1224
        • Minderhoud I.M.
        • Samsom M.
        • Oldenburg B.
        What predicts mucosal inflammation in Crohn's disease patients?.
        Inflamm Bowel Dis. 2007; 13: 1567-1572
        • Baert F.J.
        • Moortgat L.
        • Van Assche G.A.
        • et al.
        • Belgian Inflammatory Bowel Disease Research Group, North-Holland Gut Club
        Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease.
        Gastroenterology. 2010; 138: 463-468
        • D'Haens G.
        • Noman M.
        • Baert F.
        • et al.
        Endoscopic healing after infliximab treatment for Crohn's disease provides a longer time to relapse.
        Gastroenterology. 2002; 122: A-100
        • Frøslie K.F.
        • Jahnsen J.
        • Moum B.A.
        • et al.
        • IBSEN Group
        Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort.
        Gastroenterology. 2007; 133: 412-422
        • Schnitzler F.
        • Fidder H.
        • Ferrante M.
        • et al.
        Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease.
        Inflamm Bowel Dis. 2009; 15: 1295-1301
        • Rutgeerts P.
        • Vermeire S.
        • Van Assche G.
        Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?.
        Gut. 2007; 56: 453-455
        • D'Haens G.R.
        • Fedorak R.
        • Lémann M.
        • et al.
        Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease.
        Inflamm Bowel Dis. 2009; 15: 1599-1604
        • Hanauer S.B.
        • Sandborn W.J.
        • Rutgeerts P.
        • et al.
        Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC I trial.
        Gastroenterology. 2006; 130: 323-333
        • Sandborn W.J.
        • Hanauer S.B.
        • Rutgeerts P.J.
        • et al.
        Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
        Gut. 2007; 56: 1232-1239
        • Colombel J.-F.
        • Sandborn W.J.
        • Rutgeerts P.
        • et al.
        Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
        Gastroenterology. 2007; 132: 52-65
        • Sandborn W.J.
        • Rutgeerts P.
        • Enns R.
        • et al.
        Adalimumab induction therapy for Crohn disease previously treated with infliximab.
        Ann Intern Med. 2007; 146: 829-838
        • Hyams J.
        • Griffiths A.M.
        • Markowitz J.
        • et al.
        Induction and maintenance adalimumab therapy for the treatment of moderate to severe Crohn's disease in children.
        J Crohns Colitis. 2011; 5: S5
        • Best W.R.
        • Becktel J.M.
        • Singleton J.W.
        • Kern Jr, F.
        Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study.
        Gastroenterology. 1976; 70: 439-444
        • Mary J.Y.
        • Modigliani R.
        Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study.
        Gut. 1989; 30: 983-989
        • Daperno M.
        • D'Haens G.
        • Van Assche G.
        • et al.
        Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD.
        Gastrointest Endosc. 2004; 60: 505-512
        • Pineton de Chambrun G.
        • Peyrin-Biroulet L.
        • Lémann M.
        • et al.
        Clinical implications of mucosal healing for the management of IBD.
        Nat Rev Gastroenterol Hepatol. 2010; 7: 15-29
        • Rutgeerts P.
        • Feagan B.G.
        • Lichtenstein G.R.
        • et al.
        Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.
        Gastroenterology. 2004; 126: 402-413
        • Colombel J.F.
        • Sandborn W.J.
        • Reinisch W.
        • et al.
        • SONIC Study Group
        Infliximab, azathioprine, or combination therapy for Crohn's disease.
        N Engl J Med. 2010; 362: 1383-1395
        • D'Haens G.R.
        • Panaccione R.Higgins
        • et al.
        The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response.
        Am J Gastroenterol. 2011; 106: 199-212
        • Sandborn W.J.
        • Panaccione R.
        • Thakkar R.
        • et al.
        Duration of Crohn's disease affects mucosal healing in adalimumab-treated patients: Results from EXTEND.
        J Crohns Colitis Suppl. 2010; 4: S36-S37
        • Landi B.
        • Anh T.N.
        • Cortot A.
        • et al.
        • Groupe d'Etude Therapeutique des affections inflammatoires digestives
        Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial.
        Gastroenterology. 1992; 102: 1647-1653
        • Modigliani R.
        • Mary J.Y.
        • Simon J.F.
        • et al.
        • Groupe d'Etude Therapeutique des affections inflammatoires digestives
        Clinical, biological and endoscopic picture of attacks of Crohn's disease.
        Gastroenterology. 1990; 98: 811-818
        • Olaison B.
        • Sjodahl R.
        • Tagesson C.
        Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not endoscopically viewed inflammation.
        Gut. 1990; 31: 325-328